Zacks Investment Research
25 Aug 2026, 18:46 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
5 claims · each scored for market impact
IRIDEX Corporation reported a second-quarter 2026 net loss of $0.4 million (adjusted EBITDA), down from a positive $0.02 million in the prior-year period. — The swing from positive to negative adjusted EBITDA indicates deteriorating operational profitability.
-0.60Quarterly revenues declined 7% year-over-year to $12.6 million, driven primarily by a drop in retina product sales. — Revenue contraction in a core product line suggests weakening market demand or increased competition.
-0.50Cyclo G6 laser system sales fell significantly to 18 units from 35 units a year earlier due to competitive pressure and order timing. — A nearly 50% drop in system placements indicates headwinds in capturing new market share.
-0.40Continue reading
6 related stories
Search tags
Cyclo G6 probe sales grew 35% year-over-year to 17,700 units, with associated revenues increasing 19%. — Strong growth in consumables/probes provides a recurring revenue stream that partially offsets system sales declines.
+0.30Cash and cash equivalents decreased to $4.7 million from $6 million as of January 3, 2026. — A reducing cash pile increases liquidity risk for a microcap company reporting net losses.
-0.20Which stocks this story touches
The company reported a wider net loss, declining revenues, and its stock price has dropped significantly following earnings.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
3h ago
